Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
Overview of 11 peer review publications presented in 'Future Oncology'
SEATTLE, June 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reports a summary of peer reviewed publications spanning preclinical, Phase I and Phase II clinical studies wit...
Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Panel Discussant Focuses on Longer Duration of Remission among Patients Achieving a Complete Remission with Pixantrone than Complete Remissions Achieved with Standard Chemotherapy
ORLANDO, June 2 /PRNewswire-FirstCall/ -- Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that ...
Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
NATICK, Mass., May 14 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced data from its ALTITUDE Clinical Science program that show real-word survival
rates for implantable cardiac device patients exceeding
rates from clinical trials. ALTITUDE analyzes outcomes ...
Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
48-week investigational regimen yielded nearly double SVR rate compared to standard of care
Update on next-generation HCV protease inhibitor SCH 900518 presented at EASL annual meeting
COPENHAGEN, Denmark, April 23 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) toda...
CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals
'Positive Deviance' Efforts Turn the Tide on Antibiotic-Resistant Infections
PRINCETON, N.J., March 23 /PRNewswire-USNewswire/ -- The Robert Wood Johnson Foundation (RWJF) and the Plexus Institute (Plexus) today announce results from an analysis of a multifaceted methicillin-resistant Staphy...
Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
Data from a pivotal trial suggests that ofatumumab has activity in heavily pre-treated patients who have failed standard treatments
PHILADELPHIA, Dec. 8 /PRNewswire-USNewswire/ -- GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today positive results from a pivotal trial pr...
New Analysis Shows Troubling Trend in Triglyceride Levels May Be Linked to Rising Rates of Obesity
While LDL control has improved, there is an urgent need for more
comprehensive lipid control to protect against heart disease
NEW ORLEANS, Nov. 9 /PRNewswire/ -- A new 30-year analysis of the
National Health and Nutrition Examination Survey (NHANES) database
conducted by the National Lipid A...
New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
- Higher Sustained Virological Response
Rates Recognized as Marker of
Treatment Success -
SAN FRANCISCO, Calif., Nov. 1 /PRNewswire/ -- A new,
independently-conducted study being presented at the 59th Annual Meeting of
the American Association for the Study of Liver Diseases (AASLD) shows th...
TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program
NATICK, Mass. and WASHINGTON, Oct. 12 /PRNewswire-FirstCall/ -- Boston
Scientific Corporation (NYSE: BSX ) today announced results from an analysis
of nearly 7,500 patients from its TAXUS ARRIVE 1 and 2 registries, which
are designed to confirm the performance of the TAXUS(R) Express2(TM)
Pac...
Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
TAK-390MR Data Presented at the American College of Gastroenterology Annual Meeting
ORLANDO, Fla., Oct. 6 /PRNewswire/ -- Combined results from two Phase 3
studies presented at the American College of Gastroenterology Annual
Scientific Meeting (ACG) in Orlando, Fla...
Study Shows Use of AdvanDx's PNA FISH(TM) Test was Associated with an 82% Reduction in Intensive Care Unit Mortality Rates from Staphylococcus aureus Bloodstream Infections
WOBURN, Mass., July 15 /PRNewswire/ -- AdvanDx today announced that a
new study shows use of AdvanDx's PNA FISH(TM) test was associated with an
82% reduction in mortality
rates from S. aureus bloodstream infections in
the intensive care unit (ICU), a 53% reduction in overall mortality from
sta...
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
Oral presentation at international lymphoma conference shows
investigational regimen resulted in 82 percent overall survival and 78 percent progression-free survival
rates in patients receiving radioimmunotherapy
Confirmatory phase III clinical trial is pr...
Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma
Updated Clinical Phase 2 data presented at American Society of Clinical Oncology Annual Meeting
PRINCETON, N.J., June 1 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX ) today announced updated long-term follow-up and overall
survival (OS) results from a Phase 2 c...
Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda
Oncology Company, today announced the presentation of results from three
clinical trials of VELCADE based therapies that showed consistently high
complete remission(1) (CR)
rates in patients with newly diagnosed multiple
my...
New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
- Five Oral Presentations at ASCO Annual Meeting Will Further Demonstrate
the Strength of VELCADE Combinations in Front-line Multiple Myeloma -
CAMBRIDGE, Mass., May 16 /PRNewswire/ -- Millennium Pharmaceuticals,
The Takeda Oncology Company, today announced that new data from VELCADE
clinica...
Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events
Pharmacogenetic Findings May Lead to Individualized Treatment for Schizophrenia
WASHINGTON, MAY 6 /PRNewswire-FirstCall/ -- Data presented today on
Vanda Pharmaceuticals Inc.'s (Nasdaq: VNDA ) investigational drug candidate,
iloperidone, included its 4-week, sho...
BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
- BiPar Sciences Presents First Peer-Reviewed Preclinical Results for BSI-201 at 2008 AACR Annual Meeting -
SAN DIEGO, April 14 /PRNewswire/ -- BiPar Sciences, Inc. today
announced positive preclinical data demonstrating the activity of its lead
poly ADP-ribose polymerase (PAR...
TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries
NATICK, Mass. and CHICAGO, March 29 /PRNewswire-FirstCall/ -- Boston
Scientific Corporation (NYSE: BSX ) today announced results from an analysis
of 4,772 patients from its TAXUS ARRIVE 1 and 2 registries, designed to
assess the performance of the TAXUS(R) Express2(TM) Paclitaxel-Eluting
Coro...
Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C
FDA Approves Label Revisions Recommending New Weight-Based Dosing Regimen
KENILWORTH, N.J., March 27 /PRNewswire/ -- Schering-Plough Corporation
(NYSE: SGP ) today reported that the U.S. Food and Drug Administration (FDA)
has approved label revisions for PEGINTRON(TM) (peginterferon alfa-2b) a...
Influenza Vaccination Rates Among Health Care Personnel Remain Well Below National Goal
National Foundation for Infectious Diseases Highlights Critical Need for Improved Rates; Illustrates Best Practices
BETHESDA, Md., Feb. 27 /PRNewswire/ -- In response to recent data
revealing that only 42 percent of health care personnel have received their
annual influenza vacci...
Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients
Year-end 2007 long-term follow-up data continues to be positive
BETHESDA, Md., Feb. 20 /PRNewswire-FirstCall/ -- Northwest
Biotherapeutics, Inc. (OTC Bulletin Board: NWBO; AIM: NWBT and NWBS)
("NWBT" or the "Company") today announced the most recent long-term
follow-up data, as of year-end...
New Data Show Unacceptably Low Adult Immunization Rates and That Adults Unaware of Infectious Disease Threat
Experts Urge Integration of Adult Vaccines into Routine Care to Save Lives, Reduce Needless Illness
WASHINGTON, Jan. 23 /PRNewswire-USNewswire/ -- New data released today
by the Centers for Disease Control and Prevention (CDC) paint a
disappointing picture of adult immuniz...
Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma
Results underscore promise of radioimmunotherapy in ASCT and warrant randomized trial
SEATTLE, Jan. 17 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
(CTI) (Nasdaq and MTAX: CTIC) announced today that results of a phase II
clinical study, published in the Journa...
New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
- Human Genome Sciences' ABthrax(TM) shows lifesaving potential -
- HGS on track to deliver 20,000 doses to Strategic National Stockpile beginning in 2008 -
ROCKVILLE, Md., Dec. 18 /PRNewswire-FirstCall/ -- Human Genome
Sciences, Inc. (Nasdaq: HGSI ) today annou...
Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
Data Presented Today at the American Heart Association Scientific Sessions 2007 in Orlando, Florida
BOCA RATON, Fla., Nov. 7 /PRNewswire-FirstCall/ -- Nabi
Biopharmaceuticals (Nasdaq: NABI ) today announced the successful completion
of its Phase 2b trial of NicVAX(R) (Ni...
Seriously Low Vaccination Rates Cause Experts to Call for Increased Immunization Before Influenza Season Peaks
Paradigm Shift Needed to Ensure Americans Seek Vaccination Now Through
the Fall and Winter Months
WASHINGTON, Sept. 19 /PRNewswire-USNewswire/ -- New data, released
today by the Centers for Disease Control and Prevention (CDC), show
alarmingly low influenza vaccination
rates in both adults a...
Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
Milestone Payments slated for reduction from $25 Million to $7 Million, Royalties from 10-12% to 4%
HOPKINTON, Mass., May 6 /PRNewswire-FirstCall/ -- Alseres
Pharmaceuticals, Inc. (Nasdaq: ALSE ), today announced an agreement with
BioAxone Therapeutic, Inc., of Montreal, ...
Hospitalization Rates for Coronary Artery Disease Decline in the
U.S.
EVANSTON, Ill., March 20, 2007 /PRNewswire/ -- Treatment of
coronary artery disease (CAD) appears to be shifting away from the
inpatient setting, according to a study published today in The
American Journal of Cardiology.
U.S. hospitalization
rates for heart attacks (acute myocardial
infarctions...
Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term
Safety Study of Lialda (mesalamine) Presented at DDW
Post-hoc analysis shows nearly nine out of ten patients taking
once-daily Lialda remained relapse free at the end of 12 months
WASHINGTON, D.C., May 22, 2007 /PRNewswire-FirstCall/ -- A
long-term phase III, open-label 12-14 month extension study (303)
presented at the British Society of Gastroente...
Largest National U.S. Healthcare Facility MRSA Study Reveals
Infection Rates Eight Times Greater Than Previous Estimates
'Superbug' Prevalence Data from 1,237 Facilities Demonstrates
Public Health Threat; Colonization and Infections Span All States,
Across Healthcare Facility Units
SAN JOSE, Calif., June 25, 2007 /PRNewswire-USNewswire/ -- The
Association for Professionals in Infection Control and Epidemiology
(APIC...
Velcade (bortezomib) for Injection Based Therapies Achieved
Survival Rates as High as 100 Percent in Newly Diagnosed Multiple
Myeloma Patients
-- 100 percent response rate achieved with VELCADE, lenalidomide
and dexamethasone
KOS, Greece, June 28 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported on the
presentation of results from four clinical trials of VELCADE based
therapies that showed consist...
Velcade (Bortezomib) for Injection Based Therapies Produced
Complete Remission Rates as High as 54 Percent in Patients With
Previously Treated Multiple Myeloma
- 100 percent of patients treated with VELCADE, cyclophosphamide,
and prednisone alive at one year -
KOS, Greece, June 28, 2007 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. today reported on the presentation of results
from clinical trials of VELCADE based therapies that showed high
...
The American Liver Foundation Urges Cautious Optimism about CDC
Report on Declining Acute Hepatitis Infection Rates
Focus Must Remain on the Millions Still Suffering from Chronic
Hepatitis B and C
NEW YORK, March 21, 2007 /PRNewswire/ -- The Centers for Disease
Control and Prevention (CDC) has reported that significant decline
in the
rates of new acute hepatitis infections in the United States
in the last 10 ye...
Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
... death in the Western world. The highest incidence
rates are found in Japan, North America, parts of Europe, New Zealand, and Australia, and
rates are low in Africa and South-East Asia.
rates are substantially higher in men than in women.
...
Labopharm files New Drug Submission with Health Canada for novel antidepressant
...oup, four percent of patients discontinued treatment due to somnolence or sedation. The drop out rate observed in this study is comparable to drop out
rates in typical depression studies. The results of this study are found in the May 2009 issue of Psychiatry (Edgemont) (Volume 6, Number 5) ( www.psychiatr...
Nektar Therapeutics Reports Second Quarter 2009 Financial Results
...financing activities $(526) $(768)
----- -----
Effect of exchange
rates on cash and cash
equivalents (109) (164)
...
Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
...as consistent with what has previously been reported for these two agents.
rates of osteonecrosis of the jaw (ONJ) were balanced and infrequent in both trea... problem for patients with certain types of advanced cancer, with incidence
rates of nearly 100 percent in myeloma patients and as high as 75 percent in soli...
Society of Gynecologic Oncologists Issues White Paper on HPV Vaccine's Impact on Cervical Cancer Prevention
...ll as excerpts from Forum discussions regarding the limits of current screening, the impact that eliminating HPV 16/18 through vaccination may have on
rates of cervical precancer and cervical cancer screening, strategies to measure vaccine uptake and obstacles surrounding separate screening for vaccinated ...
GAA Calls on Secretary Clinton to Speak Out Against Gender-Based Violence During Her Africa Trip
...ears of conflict there.
South Africa has one of the highest reported
rates of rape in the world, coupled with one of the highest HIV
rates in the world.
As a U.S. Senator, Secretary Clinton was a co-s...
Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk
...ting of the American Society of Clinical Oncology (ASCO). It was the largest study to-date looking at how these drugs impact breast cancer recurrence
rates when taken with tamoxifen.
Antidepressants are often prescribed when women receiving tamoxifen are depressed, or to treat hot flashes -- a co...